Please enable JS

Investors & Media

2018 News Releases

Webcast ImageWebcast
CRISPR Therapeutics at RBC Capital Markets 2018 Healthcare Conference  (Replay)
02/22/18 at 8:00 a.m. ET
CRISPR Therapeutics at RBC Capital Markets 2018 Healthcare Conference
Thursday, February 22, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
Feb-21-2018CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four upcoming Investor Conferences.  2018 RBC Capital Markets Global Healthcare Conference Date: Thursday, February 22, 2018 Presentation: 8:00-8:25 AM ET Webcast available under Investor Relations tab a... 
Printer Friendly Version
Feb-08-2018CRISPR Therapeutics Announces Transition of Bill Lundberg, MD
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that Bill Lundberg, MD, is stepping down as Chief Scientific Officer of CRISPR. Going forward, Dr. Lundberg will serve as a Senior Advisor to the Company and has been named Head of CRISPR’s Scientific Advisory Board. “I have had the privilege of working with a wo... 
Printer Friendly Version
Jan-04-2018CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 5,000,000 of its common shares at a public offering price of $22.75 per share, before underwriting discounts. In addition, CRISPR Therapeutics has granted the underwriters a 30-day option to purchase up to an additio... 
Printer Friendly Version
Jan-03-2018CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $100,000,000 of its common shares. In addition, CRISPR Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of its common shares in connection with the pub... 
Printer Friendly Version
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet